New England Journal of Medicine· 2017Q1· Clinical trial
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
- 1,611citations
- Q1SCImago
- 2017year
Short summary
Oral edoxaban proved noninferior to standard low-molecular-weight heparin (dalteparin) for preventing recurrent venous thromboembolism (VTE) or major bleeding in cancer patients.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Internal Medicine
Internal MedicineMedicine